Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of NLY01 in Healthy Subjects
NCT03672604Phase 1Completed
- Sponsor
- Neuraly
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Polymer-based Nanoparticles, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegsebrenatide in Parkinson's disease (PD) (3 arms), sponsored by Neuraly. Primary endpoint: Treatment-Related Adverse Events. Started Sep 2018; status: completed.
02
Drugs
pegsebrenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03672604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672604.